Change Password!
Reset Password!
Dexibuprofen belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs).
Dexibuprofen belongs to the class of non-steroidal
anti-inflammatory drugs (NSAIDs). Dexibuprofen is used to treat painful
conditions such as arthritis, sprains and strains, period (menstrual) pain, and
dental pain.
Pharmacological
class: NSAID
Dexibuprofen works by blocking the effect of chemicals in
the body, called cyclooxygenase (COX) enzymes. These enzymes help to make other
chemicals in the body, called as prostaglandins. Some prostaglandins are
produced at sites of injury or damage, and cause pain and inflammation. By
blocking the effect of COX enzymes, fewer prostaglandins are produced, which
means pain and inflammation are eased.
The recommended adult dose is 600-900 mg/day in 2-3 divided
doses, up to 1,200 mg/day in acute exacerbations.
Plasma protein binding is 99%. Renal Excretion accounts for
90% and plasma half-life is 1.8 to 3.5 hours.
Common (affecting between 1
in 10 to 1 in 100):
Uncommon (affecting 1 in 100 to 1 in 1000):
Very rare (affecting less than 1 in 10,000):
In the efficacy study 178
inpatients with osteoarthritis of the hip were assigned to 600 or 1200 mg of
dexibuprofen or 2400 mg of racemic ibuprofen daily. The primary end-point was
the improvement of WOMAC OA index. A 1-year open tolerability study included
223 outpatients pooled from 6 studies. The main parameter was the incidence of
clinical adverse events. Evaluation of the improvement of WOMAC OA index showed
equivalence of dexibuprofen 400 mg t.i.d. compared to racemic ibuprofen 800 mg
t.i.d., with dexibuprofen being borderline superior (P = 0.055). The comparison
between 400 mg t.i.d. and 200 mg t.i.d. doses confirmed a significant superior
efficacy of dexibuprofen 400 mg (P = 0.023). The active enantiomer dexibuprofen
proved to be an effective NSAID with a significant dose-response relationship.
Compared to double dose of racemic ibuprofen, dexibuprofen was at least equally
efficient, with borderline superiority over dexibuprofen (P = 0.055). The
tolerability study in 223 patients on dexibuprofen showed clinical adverse
events of 15.2% after 12 months. The results of the studies suggest that
dexibuprofen is an effective NSAID with good tolerability.1
Comments (0)